MP81-20 IRINOTECAN AND NEDAPLATIN AS SALVAGE THERAPY FOR PATIENTS WITH ADVANCED GERM CELL TUMOR FOLLOWING INTENSIVE TREATMENT WITH CISPLATIN-BASED COMBINATION CHEMOTHERAPIES

Abstract

You have accessJournal of UrologySexual Function/Dysfunction: Penis/Testis/Urethra: Benign Disease & Malignant Disease II1 Apr 2016MP81-20 IRINOTECAN AND NEDAPLATIN AS SALVAGE THERAPY FOR PATIENTS WITH ADVANCED GERM CELL TUMOR FOLLOWING INTENSIVE TREATMENT WITH CISPLATIN-BASED COMBINATION CHEMOTHERAPIES Masatomo Nishikawa, Hideaki Miyake, and Masato Fujisawa Masatomo NishikawaMasatomo Nishikawa More articles by this author , Hideaki MiyakeHideaki Miyake More articles by this author , and Masato FujisawaMasato Fujisawa More articles by this author View All Author Informationhttps://doi.org/10.1016/j.juro.2016.02.2073AboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookTwitterLinked InEmail INTRODUCTION AND OBJECTIVES To analyze the clinical outcomes of the irinotecan plus nedaplatin (IN) regimen in patients with advanced germ cell tumors (GCTs) refractory to cisplation-based combination chemotherapies. METHODS This study included a total of 20 consecutive advanced GCT patients who were categorized into intermediate- or poor-risk GCT groups according to the International Germ Cell Consensus Classification, and were judged to show refractory or relapsed disease after BEP (bleomycin, etoposide and cisplatin) and TIP (cisplatin, ifosfamide and paclitaxel) therapies. All 20 patients subsequently received IN therapy (irinotecan, 100 mg/m2 on days 1 and 15; nedaplatin, 100 mg/m2 on day 1) every 4 weeks. RESULTS Following a median of 3 cycles of IN, 9 patients (45%) achieved the normalization of serum tumor markers. In addition, surgical resection of the residual tumors following IN was performed in 5 patients, of whom 4 were pathologically diagnosed with no viable cancer cells. At a median follow-up of 9 months, 11 patients (55%) were alive, including 7 (35%) with no evidence of disease, whereas the remaining 9 (45%) died of disease progression. The median duration of overall survival after the introduction of IN in these 20 patients was 13.4 months. Severe hematological toxicities were observed in all patients, but were manageable. Although fatal treatment-related interstitial pneumonia occurred in 1 patient, other non-hematological toxicities were generally tolerable. CONCLUSIONS Considering the markedly unfavorable characteristics of the included patients with advanced GCT who were intensively treated with cisplatin-based combination chemotherapies, IN could be regarded as having promising therapeutic activity with an acceptable toxicity profile. © 2016FiguresReferencesRelatedDetails Volume 195Issue 4SApril 2016Page: e1060 Advertisement Copyright & Permissions© 2016MetricsAuthor Information Masatomo Nishikawa More articles by this author Hideaki Miyake More articles by this author Masato Fujisawa More articles by this author Expand All Advertisement Advertisement PDF downloadLoading ...